NCT02460198View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

August 25, 2015

Primary Completion Date

September 9, 2019

Study Completion Date

February 19, 2021

Conditions
Colorectal Carcinoma
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02460198 - Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | Biotech Hunter | Biotech Hunter